Opinion statement
The accurate diagnosis of exocrine pancreatic insufficiency (EPI) helps identify those in need of pancreatic enzyme replacement therapy. Conversely, ruling out EPI identifies those in which additional evaluation should be pursued to explain their symptoms. There are many available tests that can be used to diagnose EPI; however, the tests must be tailored to each clinical scenario. Tests that are convenient but less accurate (e.g., fecal elastase-1, qualitative fecal fat determination) are best suited for patients with a high pretest probability of EPI. In contrast, tests that are highly accurate but more cumbersome (e.g., endoscopic pancreatic function testing, 72-h fecal fat collection) are favored in patients suspected to have mild EPI or an early stage of chronic pancreatitis. Additional research is needed to identify a more convenient means of accurately diagnosing at all stages of EPI.
Similar content being viewed by others
Abbreviations
- CFA:
-
Coefficient of fat absorption
- EPI:
-
Exocrine pancreatic insufficiency
- FE-1:
-
Fecal elastase-1
- MTBT:
-
13C-mixed triglyceride breath test
- PERT:
-
Pancreatic enzyme replacement therapy
- PPI:
-
Proton pump inhibitor
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance
Durno C, Corey M, Zielenski J, et al. Genotype and phenotype correlations in patients with cystic fibrosis and pancreatitis. Gastroenterology. 2002;123:1857–64.
Layer P, Yamamoto H, Kalthoff L, et al. The different courses of early- and late-onset idiopathic and alcoholic chronic pancreatitis. Gastroenterology. 1994;107:1481–7.
Tignor AS, Wu BU, Whitlock TL, et al. High prevalence of low-trauma fracture in chronic pancreatitis. Am J Gastroenterol. 2010;105:2680–6.
Duggan SN, Smyth ND, Murphy A, et al. High prevalence of osteoporosis in patients with chronic pancreatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014;12:219–28.
Czako L, Takacs T, Hegyi P, et al. Quality of life assessment after pancreatic enzyme replacement therapy in chronic pancreatitis. Can J Gastroenterol. 2003;17:597–603.
Conwell DL, Wu BU. Chronic pancreatitis: making the diagnosis. Clin Gastroenterol Hepatol. 2012;10:1088–95.
Hart PA CD. Challenges and updates in management of exocrine pancreatic insufficiency. Pancreas 2015.
Dominguez-Munoz JE. Pancreatic exocrine insufficiency: diagnosis and treatment. J Gastroenterol Hepatol. 2011;26(2):12–6.
Conwell DL, Lee LS, Yadav D, et al. American pancreatic association practice guidelines in chronic pancreatitis: evidence-based report on diagnostic guidelines. Pancreas. 2014;43:1143–62. Recently published guidelines regarding the diagnosis of chronic pancreatitis. This article provides further details about encorporating functional and structural assessments of the pancreas to diagnose chronic pancreatitis.
Conwell DL, Zuccaro G, Morrow JB, et al. Cholecystokinin-stimulated peak lipase concentration in duodenal drainage fluid: a new pancreatic function test. Am J Gastroenterol. 2002;97:1392–7.
Law R, Lopez R, Costanzo A, et al. Endoscopic pancreatic function test using combined secretin and cholecystokinin stimulation for the evaluation of chronic pancreatitis. Gastrointest Endosc. 2012;75:764–8. A recent, large study examining endoscopic pancreatic function testing. The authors demonstrated the additon of cholecystokinin stimulation to secretin stimulation did not improve the diagnosis of chronic pancreatitis.
Stevens T, Conwell DL, Zuccaro G, et al. Electrolyte composition of endoscopically collected duodenal drainage fluid after synthetic porcine secretin stimulation in healthy subjects. Gastrointest Endosc. 2004;60:351–5.
Stevens T, Conwell DL, Zuccaro Jr G, et al. A randomized crossover study of secretin-stimulated endoscopic and dreiling tube pancreatic function test methods in healthy subjects. Am J Gastroenterol. 2006;101:351–5.
Stevens T, Conwell DL, Zuccaro Jr G, et al. The efficiency of endoscopic pancreatic function testing is optimized using duodenal aspirates at 30 and 45 minutes after intravenous secretin. Am J Gastroenterol. 2007;102:297–301.
Stevens T, Conwell DL, Zuccaro Jr G, et al. A prospective crossover study comparing secretin-stimulated endoscopic and dreiling tube pancreatic function testing in patients evaluated for chronic pancreatitis. Gastrointest Endosc. 2008;67:458–66.
Stevens T, Dumot JA, Zuccaro Jr G, et al. Evaluation of duct-cell and acinar-cell function and endosonographic abnormalities in patients with suspected chronic pancreatitis. Clin Gastroenterol Hepatol. 2009;7:114–9.
Kadiyala V, Lee LS, Banks PA, et al. Cigarette smoking impairs pancreatic duct cell bicarbonate secretion. J Pancreatol. 2013;14:31–8.
Forsmark CE. Management of chronic pancreatitis. Gastroenterology. 2013;144:1282–91.
Pezzilli R, Andriulli A, Bassi C, et al. Exocrine pancreatic insufficiency in adults: a shared position statement of the Italian association for the study of the pancreas. World J Gastroenterol. 2013;19:7930–46.
Vantrappen GR, Rutgeerts PJ, Ghoos YF, Hiele MI. Mixed triglyceride breath test: a noninvasive test of pancreatic lipase activity in the duodenum. Gastroenterology. 1989;96:1126–34.
Loser C, Brauer C, Aygen S, et al. Comparative clinical evaluation of the 13C-mixed triglyceride breath test as an indirect pancreatic function test. Scand J Gastroenterol. 1998;33:327–34.
Dominguez-Munoz JE, Iglesias-Garcia J, Vilarino-Insua M, Iglesias-Rey M. 13C-mixed triglyceride breath test to assess oral enzyme substitution therapy in patients with chronic pancreatitis. Clin Gastroenterol Hepatol. 2007;5:484–8.
Keller J, Bruckel S, Jahr C, Layer P. A modified (1) (3) C-mixed triglyceride breath test detects moderate pancreatic exocrine insufficiency. Pancreas. 2011;40:1201–5.
Keller J, Meier V, Wolfram KU, et al. Sensitivity and specificity of an abbreviated (13) C-mixed triglyceride breath test for measurement of pancreatic exocrine function. United Eur Gastroenterol J. 2014;2:288–94.
Dominguez-Munoz JE, Iglesias-Garcia J, Castineira Alvarino M, et al. EUS elastography to predict pancreatic exocrine insufficiency in patients with chronic pancreatitis. Gastrointest Endosc. 2015;81:136–42.
Jonderko K, Dus Z, Szymszal M, et al. Normative values for the 13C-mixed triglyceride breath test in two age groups. Med Sci Monit. 2009;15:CR255–9.
Kalivianakis M, Verkade HJ, Stellaard F, et al. The 13C-mixed triglyceride breath test in healthy adults: determinants of the 13CO2 response. Eur J Clin Investig. 1997;27:434–42.
Sziegoleit A, Krause E, Klor HU, et al. Elastase 1 and chymotrypsin B in pancreatic juice and feces. Clin Biochem. 1989;22:85–9.
Katschinski M, Schirra J, Bross A, et al. Duodenal secretion and fecal excretion of pancreatic elastase-1 in healthy humans and patients with chronic pancreatitis. Pancreas. 1997;15:191–200.
Stein J, Jung M, Sziegoleit A, et al. Immunoreactive elastase I: clinical evaluation of a new noninvasive test of pancreatic function. Clin Chem. 1996;42:222–6.
Fischer B, Hoh S, Wehler M, et al. Faecal elastase-1: lyophilization of stool samples prevents false low results in diarrhoea. Scand J Gastroenterol. 2001;36:771–4.
Leeds JS, Oppong K, Sanders DS. The role of fecal elastase-1 in detecting exocrine pancreatic disease. Nat Rev Gastroenterol Hepatol. 2011;8:405–15.
Benini L, Amodio A, Campagnola P, et al. Fecal elastase-1 is useful in the detection of steatorrhea in patients with pancreatic diseases but not after pancreatic resection. Pancreatology. 2013;13:38–42. This study compared the diagnostic performance of FE-1 and coefficient of fat absorption in patients with a variety of pancreatic disorders. In those without a history of pancreatic surgery, steatorrhea was only observed in those with an exceedingly low FE-1 level, indicating this test is not accurate as a screening test in those without pancreatic disease.
Scotta MS, Marzani MD, Maggiore G, et al. Fecal chymotrypsin: a new diagnostic test for exocrine pancreatic insufficiency in children with cystic fibrosis. Clin Biochem. 1985;18:233–4.
Walkowiak J, Herzig KH, Strzykala K, et al. Fecal elastase-1 is superior to fecal chymotrypsin in the assessment of pancreatic involvement in cystic fibrosis. Pediatrics. 2002;110:e7.
Dominguez-Munoz JE, Iglesias-Garcia J. Oral pancreatic enzyme substitution therapy in chronic pancreatitis: is clinical response an appropriate marker for evaluation of therapeutic efficacy? JOP. 2010;11:158–62.
Compliance with Ethics Guidelines
Conflict of Interest
Phil A. Hart declares that he has no conflict of interest.
Darwin L. Conwell declares that he has no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Hart, P.A., Conwell, D.L. Diagnosis of Exocrine Pancreatic Insufficiency. Curr Treat Options Gastro 13, 347–353 (2015). https://doi.org/10.1007/s11938-015-0057-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11938-015-0057-8